Description of Treatment Patterns and Population Characteristics of Pre-dialysis CKD Patients in the Czech Republic
1 other identifier
observational
1,200
1 country
5
Brief Summary
The decision making in the Czech nephrology offices depends on the local common practice which is likely to be heterogenous. In other words, the same patient would be indicated to different therapy and regimen at different sites. To date, the practices and treatment paths have not been described. The aim of the present epidemiological research is to characterize the population of CKD patients at the point of treatment choice and to outline the motivation of nephrologist to initiate particular therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2022
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 9, 2022
CompletedStudy Start
First participant enrolled
May 16, 2022
CompletedFirst Posted
Study publicly available on registry
May 19, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2023
CompletedMarch 30, 2023
March 1, 2023
12 months
May 9, 2022
March 29, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Sociodemographic parameters
age, gender, ethnicity, health insurance company, education, marital status and cohabitation, employment status/disability, type of employment
through study completion, an average of 3 months
Secondary Outcomes (32)
Medical history and anthropometry
through study completion, an average of 3 months
Medical history and anthropometry
through study completion, an average of 3 months
Medical history and anthropometry
through study completion, an average of 3 months
Medical history and anthropometry
through study completion, an average of 3 months
Medical history and anthropometry
through study completion, an average of 3 months
- +27 more secondary outcomes
Eligibility Criteria
Adult patients with severely decreased renal function or with renal failure (CKD category 4 to 5 as per KDIGO 2012 (2), i.e., GFR \< 30 ml/min/1.73 m2 for at least 3 months) naïve to dialysis.
You may qualify if:
- Adult patient of 18 years and older
- Signed consent with processing of personal data as per the GDPR and the applicable national legal requirements
- Chronic kidney disease (CKD) category 4 to 5 characterized by GFR \< 30 ml/min/1.73m2 for at least 3 months
You may not qualify if:
- Patients on chronic dialysis
- Patient waiting for kidney transplant
- Patient requiring indication of dialysis (e.g., life-threatening changes in fluid, electrolyte, and acid-base balance, serositis, pruritus, inability to control blood pressure, lethargy or other changes in mental status, symptoms of uraemia, GFR \< 10 ml/min/1.73 m2)
- Patient with altered mental state unable to fill patient questionnaires
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (5)
FMC Nemocnice Mělník
Mělník, Central Bohemia, 27601, Czechia
FMC Sokolov
Sokolov, Karlovarský kraj, 35601, Czechia
Nemocnice Havlíčkův Brod
Havlíčkův Brod, Kraj Vysočina, 58022, Czechia
Nemocnice Jihlava
Jihlava, Kraj Vysočina, 58601, Czechia
Thetis Seirenia Brno
Brno, South Moravian, 63900, Czechia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 9, 2022
First Posted
May 19, 2022
Study Start
May 16, 2022
Primary Completion
April 30, 2023
Study Completion
June 30, 2023
Last Updated
March 30, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will not share